Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients.
Jacob Agerbo ThomsenHenning Nielsen DominiakMaria Skydt LindgrenJørgen Bjerggaard JensenPublished in: Scandinavian journal of urology (2021)
In the current study, we found that HIVEC was a well-tolerated treatment. HIVEC might be a feasible option for patients, who experienced BCG-failure or BCG-intolerance and could potentially postpone or avoid radical cystectomy.